{"id":2209,"date":"2012-04-01T12:09:00","date_gmt":"2012-04-01T10:09:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2012\/thought-leadership"},"modified":"2012-04-01T12:09:00","modified_gmt":"2012-04-01T10:09:00","slug":"thought-leadership","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2012\/thought-leadership","title":{"rendered":"\u201eThought Leadership\u201c"},"content":{"rendered":"<p>Sergio Sismondo von der Queens Universit\u00e4t in Ontario\/Kanada hat auf der diesj\u00e4hrigen Generalversammlung der International Society of Drug Bulletins (ISDB), der auch DER ARZNEIMITTELBRIEF angeh\u00f6rt, auf ein ernsthaftes Problem im medizinischen Alltag hingewiesen: Die Beeinflussung unserer Gedankenwelt durch sogenannte \u201eKey Opinion Leaders\u201c (KOL). KOL sind respektierte medizinische Experten, deren Gedanken und Handlungen einen betr\u00e4chtlichen Einfluss [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sergio Sismondo von der Queens Universit\u00e4t in Ontario\/Kanada hat auf der diesj\u00e4hrigen Generalversammlung der International Society of Drug Bulletins (ISDB), der auch DER ARZNEIMITTELBRIEF angeh\u00f6rt, auf ein ernsthaftes Problem im medizinischen Alltag hingewiesen: Die Beeinflussung unserer Gedankenwelt durch sogenannte \u201eKey Opinion Leaders\u201c (KOL). KOL sind respektierte medizinische Experten, deren Gedanken und Handlungen einen betr\u00e4chtlichen Einfluss [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3548,255,2680,3259,3260,1451,1452,3262,2229,257,843,846,1409,4411,1561],"class_list":["post-2209","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-abhaengigkeit","tag-arzneimittel","tag-aerzte","tag-aerztekongresse","tag-aerztliche-fortbildung","tag-bias","tag-interessenkonflikte","tag-key-opinion-leaders","tag-marketing","tag-medikamente","tag-pharmaindustrie","tag-pharmazeutische-unternehmer","tag-studien","tag-thought-leadership","tag-werbung"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2209"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2209\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}